KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Accured Expenses (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Change in Accured Expenses data on record, last reported at $16.8 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 181.55% year-over-year to $16.8 million; the TTM value through Dec 2025 reached -$10.2 million, down 182.93%, while the annual FY2025 figure was -$10.2 million, 182.93% down from the prior year.
  • Change in Accured Expenses reached $16.8 million in Q4 2025 per EBS's latest filing, up from -$700000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $36.1 million in Q3 2021 and bottomed at -$61.0 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is -$4.2 million, with a median of $1.9 million recorded in 2024.
  • The widest YoY moves for Change in Accured Expenses: up 443.81% in 2021, down 3736.36% in 2021.
  • A 5-year view of Change in Accured Expenses shows it stood at $10.1 million in 2021, then crashed by 703.96% to -$61.0 million in 2022, then skyrocketed by 132.46% to $19.8 million in 2023, then plummeted by 204.04% to -$20.6 million in 2024, then surged by 181.55% to $16.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $16.8 million in Q4 2025, -$700000.0 in Q3 2025, and $5.9 million in Q2 2025.